Table 4 Clinical cure rates in clinically evaluable patients at the end of treatment.
| Â | Infusion, n (%) | Bolus, n (%) | P- value |
|---|---|---|---|
Overall | 88/106 (83.0%) | 81/108 (75.0%) | 0.180 |
   Cured | 30/106 (28.3%) | 24/108 (21.3%) | 0.347 |
   Improved | 58/106 (54.7%) | 57/108 (52.8%) | 0.786 |
Culture-based therapy | 86/100 (86.0%) | 75/101 (74.3%) | 0.051 |
Empiric therapy | 4/6 (66.7%) | 6/7 (85.7%) | 0.560 |
Without concomitant ATB therapy potentially active against GNB | 80/95 (84.2%) | 76/102 (74.5%) | 0.114 |
APACHE II > 20 | 37/49 (75.5%) | 42/53 (79.2%) | 0.813 |
MIC ≥ 1.5 mg/l | 10/14 (71.4%) | 12/21 (57.1%) | 0.488 |
Type of infection | Â | Â | Â |
   Not identified | 0 | 1/1 (100%) | 1.000 |
   Abdominal | 15/18 (83.3%) | 15/27 (55.6%) | 0.063 |
   Respiratory | 52/58 (89.7%) | 47/56 (83.9%) | 0.416 |
   Soft tissues, skin | 4/5 (80.0%) | 3/4 (75.0%) | 1.000 |
   Bloodstream | 7/9 (77.8%) | 8/11 (72.7%) | 1.000 |
   Urinary tract | 7/11 (63.6%) | 5/6 (83.3%) | 0.600 |
   CNS | 3/3 (100%) | 2/2 (100%) | n/a |
   More sources | 2/2 (100%) | 1/1 (100%) | n/a |